DRKS00031101
Recruiting
Not Applicable
Cardio- and nephroprotective mechanisms of SGLT2 inhibition
niversitätsklinikum Regensburg, Klinik und Poliklinik für Innere Medizin II0 sites383 target enrollmentJanuary 20, 2023
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- I50.1
- Sponsor
- niversitätsklinikum Regensburg, Klinik und Poliklinik für Innere Medizin II
- Enrollment
- 383
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Symptomatic heart failure
- •\- nt\-pro\-BNP \> 125 pg/mL
- •\- Chronic renal failure stage G3a\-G4 (GFR 15\-59 mL/min)
- •\- No or only mild albuminuria: UACR \< 100 mg/g
Exclusion Criteria
- •\- Pre\-existing therapy with SGLT2 inhibitor (SGLT2i)
- •\- Severe symptomatic lung disease
- •\- Autoimmune diseases
- •\- Higher grade valvular disease
- •\- Anemia (hemoglobin \< 10 mg/dL)
- •\- Uncontrolled hypertension
- •o Systolic blood pressure \> 150 mmHg or
- •o Diastolic blood pressure \> 100 mgHg or
- •o \> 3 antihypertensive medications.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Investigation of renal protective effects of SGLT2 inhibitor by using renal doppler ultrasonographyJPRN-UMIN000028438Ogawa Red Cross Hospital60
Active, not recruiting
Phase 1
The RECEDE-CHF TrialType 2 diabetes and heart failureMedDRA version: 20.0Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: LLTClassification code 10010684Term: Congestive heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-003968-39-GBniversity of Dundee/NHS Tayside23
Recruiting
Phase 2
Comparison of the renoprotective effects of SGLT2 inhibitor (Empagliflozin) in diabetic and non-diabetic kidney transplantation patientsIRCT20130812014333N168Kermanshah University of Medical Sciences28
Completed
Phase 4
Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis PatientsSLELupus NephritisSGLT2 InhibitorsNCT05748925Mansoura University84
Unknown
Phase 4
Effect of SGLT2 inhibitor on Renal Function and Urinary [TIMP-2] x [IGFBP7] in Patients Hospitalized for Acute Heart Failure; A Randomized Controlled TrailAcute kidney injury and urinary [TIMP-2] x [IGFBP7] in patient hospitalized for acute heart failureAcute kidney injury, urinary [TIMP-2] x [IGFBP7], nephrocheck, acute heart failure, acute decompensated heart failure, SGLT2 inhibitor, renal function, biomarkerTCTR20221003002/A66